Abstract library

18 results for "O'Toole".
#2115 Systemic Markers of Inflammation in Neuroendocrine Tumors (NETs) and Outcomes with Everolimus: A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials
Introduction: NETs are extremely heterogeneous in nature. Despite recent advances, few biomarkers are available to consistently predict prognosis and optimize treatment selection.
Conference: 15th Annual ENETS conference (2018)
Category: Biomarkers
Presenting Author: David L Chan
#1811 Safety and Tolerability of Lanreotide Autogel/Depot (LAN) in Patients (pts) with Neuroendocrine Tumours (NETs): Pooled Analysis of Clinical Studies
Introduction: Two randomized double-blind (DB) trials demonstrated the efficacy of LAN 120mg/4weeks vs placebo in NETs: PFS improved in metastatic non-functioning intestinal/pancreatic NETs (CLARINET); less rescue medication used for carcinoid syndrome (CS) (ELECT).
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Alexandria T Phan
Keywords: Lanreotide, safety
#2112 Relationship between Metabolic Toxicity and Efficacy of Everolimus in Patients with Neuroendocrine Tumors (NETs): A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials
Introduction: Hyperglycemia and hypercholesterolemia are class effects of mTOR inhibitors such as everolimus (EVE).
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment -Targeted therapies
Presenting Author: Nicola Fazio
Authors: Fazio N, Carnaghi C, Buzzoni R, Valle J, ...
#1175 Population Pharmacokinetic (PK) Analysis of Lanreotide Autogel (LAN) in the Treatment of Patients (pts) with NETs: Pooled Analysis of Four Clinical Trials
Introduction: LAN provide antitumor effects and symptom control in NET pts.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Nuria Buil-Bruna
Keywords: PK, dosing
#484 Diagnostic Accuracy of Gallium-68 Somatostatin Receptor Positron Emission Tomography in Patients with Thoracic and Gastroenteropancreatic Neuroendocrine Tumors: A Meta-Analysis
Introduction: Gallium-68 somatostatin receptor (SMSR) positron emission tomography (PET) is a valuable diagnostic tool for patients with neuroendocrine tumors (NET). To date, a meta-analysis about the diagnostic accuracy of this functional imaging method is lacking.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Giorgio Treglia
#619 Diagnostic Accuracy of F-18-DOPA PET or PET/CT in Neuroendocrine Tumors: A Meta-Analysis
Introduction: A specific feature of NETs is amine precursor uptake and decarboxylation; this is the rationale for using PET with F-18-DOPA, a cathecholamine precursor, in diagnosis of NETs.
Conference: 10th Annual ENETS Conference (2013)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Barbara Muoio
Authors: Muoio B, Treglia G, Rufini V, ...
#955 Usefulness of the WHO Classification and of the ENETS TNM Staging System to Predict Prognosis in Patients with Rectal NENs
Introduction: WHO classification and TNM staging system have been proposed for rectal neuroendocrine neoplasia (NENs). However, their prognostic accuracy is not validated yet.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Professor Gianfranco Delle Fave
#956 Treatment Practices in European Centers with Interest in Neuroendocrine Carcinomas and High Grade (G3) Neuroendocrine Tumors
Introduction: Aggressive neuroendocrine neoplasms (NEN) encompass both poorly differentiated carcinomas (NEC) and high grade neuroendocrine tumors (G3-NET) with a Ki-67 index >20%; WHO 2010.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Ingrid Holst Olsen
#979 Characteristics and Treatments of Patients with G3 Gastroenteropancreatic Neuroendocrine Tumors (G3-NET) and Neuroendocrine Carcinoma (NEC): A European Multicenter Retrospective Study
Introduction: Data on G3-NET and NEC are limited. No standard therapy following platinum-etoposide failure is established and first-line therapy in G3-NET is not codified.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Maximilian Heetfeld
#1105 Pre-PRRT Uptake on 68Ga-DOTATOC Predicts Good Prognosis in Neuroendocrine Tumors Patients
Introduction: There is a growing need to identify PRRT-responders on an early time point during therapy.
Conference: 12th Annual ENETS Conference (2015)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Sofie Van Binnebeek
Keywords: PET, response, PRRT